The present work focuses on determining the screening utility of metalloproteinases, namely, matrilysins (MMP-7 and MMP-26) and stromelysins (MMP-3 and MMP-10), as modern tumor markers in patients with EC compared to women with benign lesions (myometrium) and healthy controls in independent analyses and in correlation with the routine marker CA125. This evidence concerns the gene MMP10 and neoplasm.